Board Meeting Details

The Board of Directors meeting was held on October 22, 2026, commencing at 2:00 PM and concluding at 5:15 PM IST.

Key Approvals

1. Unaudited Financial Results: Approved standalone and consolidated financial results for the quarter and half year ended September 30, 2026.

2. Auditor Appointment: Approved appointment of M/s Sharp & Tannan, Chartered Accountants (FRN: 003792S) as one of the Joint Statutory Auditors for a term of 3 years commencing from financial year 2027-28, subject to shareholder approval. They replace M/s Walker Chandiok & Co LLP who complete their tenure at the conclusion of the 2027 AGM.

Financial Performance (Standalone)

Quarterly Performance (Q2 FY27 vs Q2 FY26)

  • Total Income: ₹1,904.80 crore vs ₹1,509.02 crore (26.2% increase)
  • Revenue from Operations: ₹1,903.74 crore vs ₹1,508.35 crore (26.2% increase)
  • Interest Income: ₹1,800.64 crore vs ₹1,414.13 crore
  • Fees and Commission: ₹36.61 crore vs ₹28.23 crore
  • Net Gain on Fair Value Changes: ₹17.19 crore vs ₹8.28 crore
  • Bad Debt Recovery: ₹19.11 crore vs ₹16.37 crore
  • Net Gain on Derecognition: ₹30.19 crore vs ₹41.34 crore
  • Total Expenses: ₹1,233.85 crore vs ₹1,339.86 crore (7.9% decrease)
  • Finance Costs: ₹553.04 crore vs ₹479.52 crore
  • Impairment on Financial Instruments: ₹299.23 crore vs ₹525.67 crore (43.1% decrease)
  • Employee Benefits: ₹254.48 crore vs ₹219.32 crore
  • Profit Before Tax: ₹670.95 crore vs ₹169.16 crore (296.6% increase)
  • Tax Expense: ₹169.38 crore vs ₹43.35 crore
  • Net Profit: ₹501.57 crore vs ₹125.81 crore (298.6% increase)
  • EPS (Basic): ₹31.27 vs ₹7.87
  • EPS (Diluted): ₹31.12 vs ₹7.83

Half Yearly Performance (H1 FY27 vs H1 FY26)

  • Total Income: ₹3,689.23 crore vs ₹2,972.65 crore (24.1% increase)
  • Revenue from Operations: ₹3,687.25 crore vs ₹2,971.24 crore (24.1% increase)
  • Total Expenses: ₹2,358.20 crore vs ₹2,722.37 crore (13.4% decrease)
  • Profit Before Tax: ₹1,331.03 crore vs ₹250.28 crore (431.8% increase)
  • Tax Expense: ₹336.03 crore vs ₹64.28 crore
  • Net Profit: ₹995.00 crore vs ₹186.00 crore (435.0% increase)
  • EPS (Basic): ₹62.07 vs ₹11.64
  • EPS (Diluted): ₹61.79 vs ₹11.60

Balance Sheet Position (Standalone as of September 30, 2026)

  • Total Assets: ₹34,449.86 crore
  • Financial Assets:
  • Cash and Cash Equivalents: ₹1,379.03 crore
  • Loans: ₹29,293.77 crore
  • Investments: ₹1,925.95 crore
  • Total Liabilities and Equity: ₹34,449.86 crore
  • Borrowings: ₹23,467.01 crore (other than debt securities)
  • Debt Securities: ₹1,661.43 crore
  • Equity Share Capital: ₹160.52 crore
  • Other Equity: ₹8,758.48 crore

Key Ratios and Metrics (Standalone)

  • Debt-Equity Ratio: 2.86
  • Net Worth: ₹8,797.38 crore
  • Net Profit Margin: 26.98%
  • Gross Stage III (%): 1.79%
  • Net Stage III (%): 0.59%
  • Provision Coverage: 67.55%
  • CRAR (Total): 26.90%
  • Liquidity Coverage Ratio: 218.65%

ESOP Allotments

During H1 FY27, the company allotted 322,148 equity shares (face value ₹10 each) on exercise of options by employees under the Company's Employee Stock Option Schemes.

Subsidiary Information

CreditAccess India Foundation (100% subsidiary) contributed:

  • Total Assets: ₹1.25 crore as of September 30, 2026
  • Total Income: ₹7.80 crore (Q2) and ₹12.31 crore (H1)
  • Net Profit: ₹0.02 crore (Q2) and ₹0.93 crore (H1)

Auditor Profile

Sharp & Tannan Chartered Accountants (FRN: 003792S) has:

  • Pan India network with presence in 10 cities
  • Over 600+ staff members and 23 partners
  • Expertise in statutory audit of listed entities for over nine decades
  • Specialization in BFSI, Manufacturing, EPC & Infrastructure, IT, Real Estate sectors
  • Bengaluru office at Midford House, 1, Midford Gardens, Off MG Road, Bengaluru - 560001

Document Attachments

The filing includes:

  • Unaudited Financial Results (Standalone & Consolidated)
  • Limited Review Reports (Standalone & Consolidated)
  • Disclosures under Regulation 52 & 54 of Listing Regulations
  • Annexure 1 with auditor appointment details
  • Statement of Security Cover for listed NCDs